Douglas Joshua

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10532988/publications.pdf

Version: 2024-02-01

35 papers	2,783 citations	471061 17 h-index	395343 33 g-index
35 all docs	35 docs citations	35 times ranked	3600 citing authors

#	Article	IF	Citations
1	Alcohol and tobacco use and risk of multiple myeloma: A caseâ€control study. EJHaem, 2022, 3, 109-120.	0.4	3
2	Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. Internal Medicine Journal, 2021, 51, 1707-1712.	0.5	1
3	Inverse relationship between oligoclonal expanded CD69â˜ TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients. Blood Advances, 2020, 4, 4593-4604.	2.5	16
4	A liquid biopsy to detect multidrug resistance and disease burden in multiple myeloma. Blood Cancer Journal, 2020, 10, 37.	2.8	24
5	Mass Cytometry Discovers Two Discrete Subsets of CD39â˜Treg Which Discriminate MGUS From Multiple Myeloma. Frontiers in Immunology, 2019, 10, 1596.	2.2	18
6	Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study. Leukemia and Lymphoma, 2019, 60, 2122-2133.	0.6	12
7	Carfilzomibâ€“dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leukemia and Lymphoma, 2018, 59, 1364-1374.	0.6	6
8	Quality of Patient-Centered Care Provided to Patients Attending Hematological Cancer Treatment Centers. International Journal of Environmental Research and Public Health, 2018, 15, 549.	1.2	8
9	Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Leukemia and Lymphoma, 2017, 58, 2501-2504.	0.6	22
10	Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 1327-1337.	5.1	320
11	High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. British Journal of Clinical Pharmacology, 2016, 82, 149-159.	1.1	43
12	The T Cell in Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 537-542.	0.2	43
13	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncology, The, 2016, 17, 27-38.	5.1	723
14	A CD2 highâ€expressing stressâ€resistant human plasmacytoid dendriticâ€cell subset. Immunology and Cell Biology, 2016, 94, 447-457.	1.0	34
15	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. Journal of Clinical Oncology, 2016, 34, 1544-1557.	0.8	294
16	Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifyingFGFR3up-regulation. Leukemia and Lymphoma, 2015, 56, 2714-2716.	0.6	2
17	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, BloodÂand Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 2039-2051.	2.0	146
18	Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup. Blood, 2015, 126, 1844-1844.	0.6	5

#	Article	IF	Citations
19	Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866). Blood, 2015, 126, 30-30.	0.6	8
20	Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866). Blood, 2015, 126, 4250-4250.	0.6	27
21	Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866). Blood, 2015, 126, 729-729.	0.6	3
22	Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leukemia and Lymphoma, 2014, 55, 1090-1098.	0.6	66
23	Multiple Myeloma Surveillance Counterpoint: Australia. , 2013, , 493-500.		0
24	Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma. OncoImmunology, 2012, 1, 1658-1660.	2.1	21
25	CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis. Blood, 2012, 120, 2055-2063.	0.6	82
26	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia, 2012, 26, 149-157.	3.3	664
27	Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British Journal of Clinical Pharmacology, 2010, 69, 484-497.	1.1	66
28	Clonal Expansions of Cytotoxic T Cells in the Blood of Patients with Waldenstrom's Macroglobulinaemia Are Anergic and Disappear After Nucleoside Analogue Therapy.. Blood, 2009, 114, 1820-1820.	0.6	3
29	Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents. Journal of Clinical Oncology, 2008, 26, 2761-2766.	0.8	76
30	Characterization of Bortezomib Resistance in Multiple Myeloma Cell Lines. Blood, 2008, 112, 2639-2639.	0.6	1
31	Multiple Myeloma: Challenges and Opportunities. , 2005, 113, 1-4.		4
32	An Oral Iron Chelator and Quality of Life.. Blood, 2005, 106, 5553-5553.	0.6	4
33	The Use of a Commercially Available Immunoassay to Determine the Level of Interleukin-6 in the Serum of Patients with Myeloma. Leukemia and Lymphoma, 1991, 5, 151-155.	0.6	19
34	CD23 ANTIGEN EXPRESSION IN CLL. British Journal of Haematology, 1989, 72, 598-598.	1.2	13
35	PERIPHERAL BLOOD LYMPHOCYTE SUBSETS AND NATURAL KILLER CELL NUMBER AND FUNCTION DURING Î±â€¦INTERFERON TREATMENT FOR HAIRY CELL LEUKEMIA. Australian and New Zealand Journal of Medicine, 1988, 18, 897-899.	0.5	6